On the occasion of International Alzheimer’s Day, celebrated this Saturday, the need to promote new technologies, scientific advances and more effective innovation in pharmacology is more urgent than ever in Spain. The country faces a growing public health challenge, with more than 800,000 people affected for this devastating neurodegenerative disease. This is why the PP has accused the President of the Government, Pedro Sánchez, of once again breaking his promises and leaving these patients without health innovation.
The Popular Party has asked the Executive to promote access to therapeutic, pharmacological and technological innovations to care for Alzheimer’s patients with agility and safety.
Through a manifesto published on the occasion of World Day of this pathology, the PP in turn urged the government carry out a global socio-health approach linked to a quality dependency system, with a maximum period of 30 days to benefit from the services and with 50% state funding.
In this sense, he attacked the President of the Government, Pedro Sánchez, stating that “This ongoing demand remains an unfulfilled promise.” of his investiture.
More broadly, the PP indicated that these demands aim to ensure sufficient resources in the interest of promoting and improving personal autonomy in the early stages of this disease, as well as continuing to work on possible treatments.
Similarly, he cited that these issues are already supported in Article 44 of the Constitution: “public authorities will promote science and scientific research and technical for the benefit of the general interest.
However, the medical and technological advances needed to improve the quality of life of these patients and their families are lagging behind in Spain.
It is crucial to invest in more resources for research, to integrate new technologies into diagnosis and treatment and to “ensure that Spanish patients have access to the latest advances in pharmacology”. Only through a “robust and coordinated strategy” can real hope be offered to those suffering from this disease.
Alzheimer
Alzheimer’s disease in Spain is one of the the main causes of dependency and mortalitybeing the most common form of dementia. The prevalence is increasing, with 800,000 people diagnosed: between 60% and 80% of all cases of dementia.
Thus, this pathology not only affects the patient, but also has a profound impact on his families and caregivers. This generates a high cost both at the individual level and for the health system. The total cost of the disease, including medical expenses, lost productivity and informal care, is estimated to exceed 24 billion euros per year.
There is currently no definitive cure for Alzheimer’s disease, and available treatments –Many have not arrived in Spain for six years-they only delay the progression of symptoms. However, advances in genetic research, biotechnology and artificial intelligence are opening new avenues for early diagnosis and possible therapies.
Access to innovation and treatments
One of the main challenges in Spain is to guarantee access to innovative treatments. Although new drugs have been developed in other countries, Like amyloid protein inhibitors, Spanish patients face delays in availability of these treatments due to the long approval processes and lack of public fundingThis situation has drawn criticism from patient organizations and health experts.
